Edwards Lifesciences 

€63.06
-€2.4-3.67% Friday 16:30

统计数据

当日最高
63.16
当日最低
61.96
52周最高
-
52周最低
-
成交量
26
平均成交量
-
市值
-
市盈率
-
股息收益率
-
股息
-

即将到来

收益

30Jan预期
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
Q3 2024
下一个
0.56
0.61
0.65
0.7
预期每股收益
0.562526
实际每股收益
N/A

人们还关注

此列表基于关注EWL.XETRA的Stock Events用户的观察列表。这不是投资建议。

竞争者

这个列表是基于最近市场事件的分析。这不是投资建议。
Medtronic
MDT
市值113.61B
Medtronic在心脏瓣膜市场上直接与爱德华兹生命科学公司竞争,包括经导管主动脉瓣置换(TAVR)技术。
Boston Scientific
BSX
市值120.45B
波士顿科学公司在介入心脏病学领域竞争,提供与爱德华兹生命科学的心脏瓣膜解决方案相媲美的产品。
Abbott Laboratories
ABT
市值197.08B
Abbott Laboratories提供一系列心血管设备,包括与爱德华兹的产品竞争的二尖瓣和三尖瓣修复和更换技术。
Stryker
SYK
市值137.35B
Stryker在医疗器械领域竞争,包括神经技术和脊柱产品,这可以看作是对爱德华兹生命科学心血管重点的间接竞争。
Johnson & Johnson
JNJ
市值399.26B
强生公司通过其医疗器械部门在各个医疗保健领域竞争,包括心血管领域,与爱德华兹生命科学公司竞争。
Zimmer Biomet
ZBH
市值23.51B
Zimmer Biomet主要以骨科著名,已进军心血管领域,成为爱德华兹生命科学的竞争对手。
Intuitive Surgical
ISRG
市值175.06B
Intuitive Surgical的机器人辅助手术系统可用于心血管手术,间接与爱德华兹生命科学的外科心脏瓣膜解决方案竞争。
Edwards Lifesciences
EW
市值42.14B
爱德华兹生命科学公司通过其多样化的心脏瓣膜产品与自身竞争,不断创新以取代旧技术。
Baxter International
BAX
市值19.36B
Baxter International在更广泛的医疗设备市场上竞争,包括用于危重护理的产品,这可能与爱德华兹生命科学的心血管重点重叠。
Integra Lifesciences
IART
市值1.58B
Integra LifeSciences虽然更专注于神经外科和再生技术,但在医疗器械市场上竞争,提供一些可用于心血管手术的产品。

关于

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Show more...
首席执行官
员工
15700
国家
DE
ISIN
US28176E1082
WKN
000936853

上市公司